shock
Conditions
Interventions
1:routin therapy
2:routin therapy +ulinastatin 40wU tid×7d
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria can be included in this study: 1. infection or suspected infection 2. the clinical manifestation of low perfusion (conforming to at least one of the following) (1) consciousness changes: including irritability, indifference, delirium, and coma; (2) the amount of urine is decreased: adequate rehydration is still 2s. 3. lactic acid > 2mmol/L or hypotension (systolic blood pressure < 90mmHg, or pulse pressure < 20mmHg, or the systolic blood pressure of the original high blood pressure from a baseline decline of greater than 40mmHg); 4. aged 18 to 80 years.
Exclusion criteria
Exclusion criteria: Patients will be excluded from the study if they are subject to any of the following criteria, based on the physician's judgment. 1. patients who can't observe the blood vessels under the tongue: oral surgery, oral bleeding, etc 2. pregnant and breastfeeding women; 3. use traditional Chinese medicine for activating blood circulation to dissipate blood stasis, thoracic glands, or glucocorticoids; 4. infection control poor patient; 5. after chemotherapy, radiation therapy, organ transplantation and immunosuppressant and excessive application in two days before the onset of nonsteroidal anti-inflammatory drugs (such as 1 g/day or more Aspirin); 6. give up treating patients; 7. the estimated 48h deaths are expected; 8. abdominal pressure > 10mmHg (13.3 cmH2O); 9. there is an allergy history of ulinastatin or any ingredient or preservative; 10. unable to obtain informed consent or authorization; 11. to participate in other exploratory clinical trials within six months of screening; 12. do not agree to comprehensive, positive life support treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| microvascular flow index, MFI; | — |
Secondary
| Measure | Time frame |
|---|---|
| microvascular flow index, MFI;proportion of perfused small vessels, PPV;perfused small vessel density, PVD;total vessel density, TVD;Arterial lactate;?????;incidence of new organ failure;delta SOFA;all-cause mortality;fuild volume until BP return to normal;totoal dosage of noradrenaline;proportion of using vasoactive agent;The duration of hypotension; | — |
Countries
China
Contacts
Public ContactSun Yunbo
The Affiliated Hospital of Qingdao University
Outcome results
None listed